Abstract:Pyridomycin, a cyclodepsipeptide with potent antimycobacterial activity, specifically inhibits the InhA enoyl reductase of Mycobacterium tuberculosis. Structure-activity relationship studies indicated that the enolic acid moiety in the pyridomycin core system is an important pharmacophoric group, and the natural configuration of the C-10 hydroxyl contributes to the bioactivity of pyridomycin. The ring structure of pyridomycin was generated by the nonribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) hybrid system (PyrE-PyrF-PyrG). Bioinformatics analysis reveals that short-chain dehydrogenase/reductase (SDR) family protein Pyr2 functions as a 3-oxoacyl acyl carrier protein (ACP) reductase in the pyridomycin pathway. Inactivation of pyr2 resulted in accumulation of pyridomycin B, a new pyridomycin analogue featured with enol moiety in pyridyl alanine moiety and a saturated 3-methylvaleric acid group. The elucidated structure of pyridomycin B suggests that rather than functioning as a post-tailoring enzyme, Pyr2 catalyzes ketoreduction to form the C-10 hydroxyl group in pyridyl alanine moiety and the double bond formation of the enolic acid moiety derived from isoleucine when the intermediate assembled by PKS-NRPS machinery is still tethered to the last NRPS module in a special energy-saving manner. Ser-His-Lys residues constitute the active site of Pyr2, which is different from the typically conserved Tyr-based catalytic triad in the majority of SDRs. Site-directed mutation identified that His154 in the active site is a critical residue for pyridomycin B production. These findings will improve our understanding of pyridomycin biosynthetic logic, identify the missing link for the double bound formation of enol ester in pyridomycin, and enable the creation of chemical diversity of pyridomycin derivatives. IMPORTANCE Tuberculosis (TB) is one of the world's leading causes of death by infection. Recently, pyridomycin, the antituberculous natural product from Streptomyces has garnered considerable attention for being determined as a target inhibitor of InhA enoyl reductase of Mycobacterium tuberculosis. In this study, we report a new pyridomycin analogue from mutant HTT12, demonstrate the essential role of a previously ignored gene pyr2 in pyridomycin biosynthetic pathway, and imply that Pyr2 functions as a trans ketoreductase (KR) contributing to the formation of functional groups of pyridomycin utilizing a distinct catalytic mechanism. As enol moiety are important for pharmaceutical activities of pyridomycin, our work would expand our understanding of the mechanism of SDR family proteins and set the stage for future bioengineering of new pyridomycin derivatives.

Pyrazinoic acid, the active form of the anti-tuberculosis drug pyrazinamide, and aromatic carboxylic acid analogs are protonophores

Thiol Stress Fuels Pyrazinamide Action Against Mycobacterium tuberculosis

Pyrazinoic Acid Inhibits the Bifunctional Enzyme (rv2783) in Mycobacterium Tuberculosis by Competing with Tmrna

Studying the dynamics of the drug processing of pyrazinamide in Mycobacterium tuberculosis

Anti-tubercular potential and pH-driven mode of action of salicylic acid derivatives

Oxidative stress drives potent bactericidal activity of pyrazinamide against Mycobacterium tuberculosis

Enhancement of the Antituberculosis Activity of Weak Acids by Inhibitors of Energy Metabolism but Not by Anaerobiosis Suggests That Weak Acids Act Differently from the Front-Line Tuberculosis Drug Pyrazinamide.

Pyrazinamide Inhibits Trans-Translation in Mycobacterium Tuberculosis

Characterization of Pyridomycin B Reveals the Formation of Functional Groups in Antimycobacterial Pyridomycin

Structural Insights of Catalytic Mechanism in Mutant Pyrazinamidase of Mycobacterium Tuberculosis.

Antitubercular potential and pH‐driven mode of action of salicylic acid derivatives

Aspartate Decarboxylase (pand) As a New Target of Pyrazinamide in Mycobacterium Tuberculosis.

Identification of Novel Mutations in LprG (rv1411c), Rv0521, Rv3630, Rv0010c, Ppsc, Cyp128 Associated with Pyrazinoic Acid/pyrazinamide Resistance in Mycobacterium Tuberculosis

Lead Compounds and Key Residues of Ribosomal Protein S1 in Drug-Resistant Mycobacterium Tuberculosis.

Mechanisms of Pyrazinamide Action and Resistance.

Structural basis for targeting the ribosomal protein S1 of Mycobacterium tuberculosis by pyrazinamide.

Nutrient-Starved Incubation Conditions Enhance Pyrazinamide Activity Against Mycobacterium Tuberculosis

Benzo[d]Thiazole-2-Carboxamides/Carbanilides as New Anti-TB Chemotypes Inhibiting the Mycobacterial ATP-Phosphoribosyl Transferase (HisG)

Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives As Drug Resistant Antituberculosis Agents.

Pyrrole‐Thiazolidin‐4‐one Analogues Exhibit Promising Anti‐Tuberculosis Activity

Insights into the Mechanisms of the Pyrazinamide Resistance of Three Pyrazinamidase Mutants N11K, P69T, and D126N.